Compare FTFT & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | SHPH |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.2M |
| IPO Year | 2008 | 2022 |
| Metric | FTFT | SHPH |
|---|---|---|
| Price | $1.16 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 233.8K | ★ 1.2M |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,829,805.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.56 | $0.12 |
| 52 Week High | $4.03 | $5.59 |
| Indicator | FTFT | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 40.87 |
| Support Level | $0.94 | $0.65 |
| Resistance Level | $1.32 | $1.13 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 9.97 | 13.20 |
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.